Table 1—

Baseline clinical and metabolic characteristics of high-risk African Americans with NGT

Clinical characteristics
n81
 Age (years)41.5 ± 4.8
 Sex ratio (women/men)54/27
 Body weight (kg)89.9 ± 10.3
 Height (m)1.68 ± 0.1
 BMI (kg/m2)31.3 ± 3.6
 Lean body mass (kg)61.7 ± 7.0
 Body fat mass (%)37.4 ± 4.3
 Waist-to-hip ratio0.90 ± 0.10
Metabolic parameters
 OGTT
  Fasting serum glucose (mg/dl)78.3 ± 8.9
  2-h serum glucose (mg/ml)95 ± 11
  Fasting serum insulin (μU/ml)13.7 ± 1.9
  2-h serum insulin (μU/ml)78 ± 4.9
  Fasting serum C-peptide (ng/ml)2.68 ± 0.35
  2-h serum C-peptide (ng/ml)9.31 ± 1.13
 IVGTT
  AIRpeak at t = 5 min
  Peak glucose (mg · dl−1 · min−1)221 ± 32
  Peak insulin (μU/ml)108 ± 88
  Peak C-peptide (ng/ml)6.85 ± 3.20
  Acute first phase (AIRFSIGTT)
  Glucose (mg · dl−1 · min−1)1,217 ± 245
  Insulin (μU · ml−1 · min−1)354 ± 23
  C-peptide (ng · ml−1 · min−1)17 ± 0.16
Insulin sensitivity indexes
Si (×10−4 × min−1 [μU/ml]−1)2.48 ± 0.33
Sg (×10−2 × min−1)2.48 ± 0.31
HOMA-IR2.56 ± 1.4
HOMA-%B391 ± 54
  • Data are means ± SD. AIRFSIGTT, acute insulin response to a frequently sampled intravenous glucose tolerance test; IVGTT, intravenous glucose tolerance test.